Clinical trials: Hypoparathyroidism
Down Syndrome, Edwards Syndrome
Whole Blood Specimen Collection From Pregnant Subjects
To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.
- Conditions
- Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome
- Trial name
- NCT02430584
- Testing
- Observational - no intervention
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Progenity, Inc.
22q11.2 Deletion Syndrome
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD.
- Trial name
- NCT02895906
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
DiGeorge Syndrome, Hypoparathyroidism
Parathyroid and Thymus Transplantation in DiGeorge #931
This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess…
- Conditions
- DiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge Syndrome
- Trial name
- NCT00566488
- Testing
- Thymus/Parathyroid Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Chronic Hypoparathyroidism, Endocrine System Diseases
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP).
- Conditions
- Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- CALYPSO (NCT05778071)
- Testing
- eneboparatide
- Where
- 54 sites in United States, Canada and 11 more
- Volunteers
- 165 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypoparathyroidism, Endocrine System Diseases
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
During the first four weeks of the trial, participants were randomly assigned to one of four groups: three groups received fixed doses of TransCon PTH and one group received placebo.
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- PaTH Forward (NCT04009291)
- Testing
- TransCon PTH
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 59 people
- Sponsor
- Ascendis Pharma A/S
DiGeorge Anomaly
Serum-Free Thymus Transplantation in DiGeorge Anomaly
The study purpose is to determine if thymus tissue cultured in a serum-free (SF) solution is a safe and effective treatment for atypical and typical complete DiGeorge anomaly. [Funding Source - FDA OOPD]
- Trial name
- SerumFree (NCT00849888)
- Testing
- Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hypoparathyroidism, Parathyroid Hormone Deficiency
PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
This study is limited to conduct in China only. The primary objective is to assess the treatment effect of daily TransCon PTH on serum calcium (sCa) levels within the normal range and stopping from therapeutic doses of active…
- Conditions
- Hypoparathyroidism, Parathyroid Hormone Deficiency, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- NCT05387070
- Testing
- TransCon PTH
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Visen Pharmaceuticals (Shanghai) Co., Ltd.
Complete DiGeorge Anomaly, DiGeorge Syndrome
Thymus Transplantation Safety-Efficacy
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection.
- Conditions
- Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- NCT01220531
- Testing
- Cultured Thymus Tissue
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hypoparathyroidism
A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.
- Trial name
- NCT06988670
- Testing
- EXT608
- Where
- Argentina
- Volunteers
- 35 people
- Sponsor
- Extend Biosciences Inc.
DiGeorge Syndrome, DiGeorge Anomaly
Thymus Transplantation With Immunosuppression
The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly.
- Conditions
- DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- 884 (NCT00579709)
- Testing
- Thymus Tissue for Transplantation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hypoparathyroidism
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
This is a multi-center, placebo-controlled, randomized, double-blind, multiple-ascending dose study in patients with hypoparathyroidism.
- Trial name
- NCT04209179
- Testing
- PCO371
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Chugai Pharmaceutical
Hypoparathyroidism
Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
To provide palopegteriparatide (TransCon PTH), an investigational parathyroid hormone (PTH) replacement therapy in an expanded access setting for adult patients with hypoparathyroidism who have previously received PTH-treatment…
- Trial name
- NCT05654701
- Testing
- Palopegteriparatide (TransCon PTH)
- Sponsor
- Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism, Chronic Hypoparathyroidism
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
- Trial name
- RECLAIM-HP (NCT07805356)
- Testing
- Encaleret
- Where
- 5 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Hypoparathyroidism, Endocrine System Diseases
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
During the first 26 weeks of the trial, participants were randomly assigned to one of two groups: one group received TransCon PTH and one group received placebo.
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- PaTHway (NCT04701203)
- Testing
- TransCon PTH
- Where
- 21 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
This trial will enroll adolescents between ages of ≥12 and <18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it…
- Trial name
- NCT07706764
- Testing
- Palopegteriparatide
- Where
- 3 sites in France, Poland
- Volunteers
- 12 people
- Sponsor
- Ascendis Pharma A/S
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hypoparathyroidism
A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism
This clinical study aims to evaluate the safety and efficacy of repeated dosing of recombinant human parathyroid hormone (rhPTH[1-84]) in Japanese participants with chronic hypoparathyroidism for a 26-week period.
- Trial name
- NCT03878953
- Testing
- rhPTH(1-84)
- Where
- 10 sites in Japan
- Sponsor
- Shire
22q11 Deletion Syndrome
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.
- Trial name
- NCT05290493
- Testing
- NB-001
- Where
- 4 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Nobias Therapeutics, Inc.
Hypoparathyroidism
A Registry for Participants With Chronic Hypoparathyroidism
The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) treatment in participants with chronic hypoparathyroidism under conditions of…
- Trial name
- PARADIGHM (NCT01922440)
- Testing
- No intervention
- Where
- 100 sites in United States, Austria and 9 more
- Volunteers
- 1,339 people
- Sponsor
- Takeda
Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed…
- Trial name
- NCT07264634
- Testing
- Palopegteriparatide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ascendis Pharma A/S